Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
Identifieur interne : 002284 ( Main/Exploration ); précédent : 002283; suivant : 002285Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
Auteurs : J. Knoll [Hongrie]Source :
- Biomedicine & Pharmacotherapy [ 0753-3322 ] ; 1995.
English descriptors
- KwdEn :
Abstract
(−)Deprenyl (selegiline, jumex, eldepryl, movergan), a close structural relative to phenylethylamine (PEA), is a drug with a unique pharmacological spectrum. It is a highly potent and selective, irreversible inhibitor of B-type monoamine oxidase (MAO), a predominantly glial enzyme in the brain. The activity of this enzyme significantly increases with age. (−)deprenyl, the first selective inhibitor of MAO-B described in literature, has become the universally used research tool for selectively blocking B-type MAO. It is the only selective MAO-B inhibitor in clinical use.(−)Deprenyl interferes with the uptake of catecholamines and indirectly acting sympathomimetics because it is handled by the catecholaminergic neuron in a way similar to the physiological substances transported through the axonal end organ and vesicular membrane. The unique behavior of (−)deprenyl is that, in striking contrast to PEA and its relatives it does not displace the transmitter from storage, ie it is not a releaser. The net result is that (−)deprenyl inhibits the releasing effect of tyramine, and at present, is the only safe MAO inhibitor than can be administered without dietary precautions.Maintenance on (−)deprenyl selectively enhances superoxide dismutase (SOD) and catalase activity in the striatum. This effect is unrelated to its effect on MAO-B and the inhibitory effects of the drug on neurotransmitter uptake. Maintenance on (−)deprenyl facilitates the activity of the catecholaminergic system in the brain, and this effect, too, is unrelated to either its effects on MAO or on neurotransmitter uptake. (−)Deprenyl protects the nigrostriatal dopaminergic neurons against selective neurotoxins (6-hydroxydopamine, MPTP, DSP-4). Maintenance on (−)deprenyl prevents the characteristic age-related morphological changes in the neuromelanin granules of the neurocytes in the substantia nigra.All in all, (−)deprenyl increases the activity of the nigrostriatal dopaminergic system and slows its age-related decline. Maintenance of male rats on (−)deprenyl delays the loss of the capacity to ejaculate, slows the decline of learning and memory, and significantly lengthens the lifespan as compared with saline-treated rats.Parkinson's disease patients on levodopa plus (−)deprenyl (10 mg daily) live significantly longer than those on levodopa alone. (−)Deprenyl is the first drug that retards the progress of Parkinson's disease. Newly diagnosed Parkinson's disease patients maintained on (−)deprenyl need levodopa significantly later than their placebo-treated peers. Maintenance on (−)deprenyl improves significantly the performance of patients with Alzheimer's disease. It is concluded that Parkinson's disease and Alzheimer's disease patients need to be treated daily with 10 mg (−)deprenyl from diagnosis until death, irrespective of other medication.We propose that the healthy population be maintained on 10–15 mg (−)deprenyl weekly starting at age 45 in order to combat the age-related decline of the nigrostriatal dopaminergic neurons. Prophylactic (−)deprenyl medication seems to offer a reasonable prospect of improving the quality of life in the later decades, delaying the time of natural death and decreasing the susceptibility of age-related neurological diseases, like Parkinson's diesase and Alzheimer's disease.
Url:
DOI: 10.1016/0753-3322(96)82619-9
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes</title>
<author><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J" last="Knoll">J. Knoll</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BD4040693F16956A2668D9EC39B0B4224E2FB7B7</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1016/0753-3322(96)82619-9</idno>
<idno type="url">https://api.istex.fr/document/BD4040693F16956A2668D9EC39B0B4224E2FB7B7/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000341</idno>
<idno type="wicri:Area/Main/Curation">000292</idno>
<idno type="wicri:Area/Main/Exploration">002284</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes</title>
<author><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J" last="Knoll">J. Knoll</name>
<affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country>
<wicri:regionArea>Department of Pharmacology, Semmelweis University of Medicine, POB 370, Budapest H-1445</wicri:regionArea>
<placeName><settlement type="city">Budapest</settlement>
<region nuts="2">Hongrie centrale</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Biomedicine & Pharmacotherapy</title>
<title level="j" type="abbrev">BIOPHA</title>
<idno type="ISSN">0753-3322</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1995">1995</date>
<biblScope unit="volume">49</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="187">187</biblScope>
<biblScope unit="page" to="195">195</biblScope>
</imprint>
<idno type="ISSN">0753-3322</idno>
</series>
<idno type="istex">BD4040693F16956A2668D9EC39B0B4224E2FB7B7</idno>
<idno type="DOI">10.1016/0753-3322(96)82619-9</idno>
<idno type="PII">0753-3322(96)82619-9</idno>
<idno type="ArticleID">96826199</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0753-3322</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(−)deprenyl</term>
<term>Parkinson's disease</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">(−)Deprenyl (selegiline, jumex, eldepryl, movergan), a close structural relative to phenylethylamine (PEA), is a drug with a unique pharmacological spectrum. It is a highly potent and selective, irreversible inhibitor of B-type monoamine oxidase (MAO), a predominantly glial enzyme in the brain. The activity of this enzyme significantly increases with age. (−)deprenyl, the first selective inhibitor of MAO-B described in literature, has become the universally used research tool for selectively blocking B-type MAO. It is the only selective MAO-B inhibitor in clinical use.(−)Deprenyl interferes with the uptake of catecholamines and indirectly acting sympathomimetics because it is handled by the catecholaminergic neuron in a way similar to the physiological substances transported through the axonal end organ and vesicular membrane. The unique behavior of (−)deprenyl is that, in striking contrast to PEA and its relatives it does not displace the transmitter from storage, ie it is not a releaser. The net result is that (−)deprenyl inhibits the releasing effect of tyramine, and at present, is the only safe MAO inhibitor than can be administered without dietary precautions.Maintenance on (−)deprenyl selectively enhances superoxide dismutase (SOD) and catalase activity in the striatum. This effect is unrelated to its effect on MAO-B and the inhibitory effects of the drug on neurotransmitter uptake. Maintenance on (−)deprenyl facilitates the activity of the catecholaminergic system in the brain, and this effect, too, is unrelated to either its effects on MAO or on neurotransmitter uptake. (−)Deprenyl protects the nigrostriatal dopaminergic neurons against selective neurotoxins (6-hydroxydopamine, MPTP, DSP-4). Maintenance on (−)deprenyl prevents the characteristic age-related morphological changes in the neuromelanin granules of the neurocytes in the substantia nigra.All in all, (−)deprenyl increases the activity of the nigrostriatal dopaminergic system and slows its age-related decline. Maintenance of male rats on (−)deprenyl delays the loss of the capacity to ejaculate, slows the decline of learning and memory, and significantly lengthens the lifespan as compared with saline-treated rats.Parkinson's disease patients on levodopa plus (−)deprenyl (10 mg daily) live significantly longer than those on levodopa alone. (−)Deprenyl is the first drug that retards the progress of Parkinson's disease. Newly diagnosed Parkinson's disease patients maintained on (−)deprenyl need levodopa significantly later than their placebo-treated peers. Maintenance on (−)deprenyl improves significantly the performance of patients with Alzheimer's disease. It is concluded that Parkinson's disease and Alzheimer's disease patients need to be treated daily with 10 mg (−)deprenyl from diagnosis until death, irrespective of other medication.We propose that the healthy population be maintained on 10–15 mg (−)deprenyl weekly starting at age 45 in order to combat the age-related decline of the nigrostriatal dopaminergic neurons. Prophylactic (−)deprenyl medication seems to offer a reasonable prospect of improving the quality of life in the later decades, delaying the time of natural death and decreasing the susceptibility of age-related neurological diseases, like Parkinson's diesase and Alzheimer's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Hongrie</li>
</country>
<region><li>Hongrie centrale</li>
</region>
<settlement><li>Budapest</li>
</settlement>
</list>
<tree><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J" last="Knoll">J. Knoll</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002284 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002284 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:BD4040693F16956A2668D9EC39B0B4224E2FB7B7 |texte= Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes }}
This area was generated with Dilib version V0.6.23. |